Peter Spanogiannopoulos
Peter Spanogiannopoulos
No verified email
Cited by
Cited by
The comprehensive antibiotic resistance database
AG McArthur, N Waglechner, F Nizam, A Yan, MA Azad, AJ Baylay, ...
Antimicrobial agents and chemotherapy 57 (7), 3348-3357, 2013
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
P Spanogiannopoulos, EN Bess, RN Carmody, PJ Turnbaugh
Nature Reviews Microbiology 14 (5), 273-287, 2016
The tetracycline resistome
M Thaker, P Spanogiannopoulos, GD Wright
Cellular and Molecular Life Sciences 67, 419-431, 2010
Identifying producers of antibacterial compounds by screening for antibiotic resistance
MN Thaker, W Wang, P Spanogiannopoulos, N Waglechner, AM King, ...
Nature biotechnology 31 (10), 922-927, 2013
Cooking shapes the structure and function of the gut microbiome
RN Carmody, JE Bisanz, BP Bowen, CF Maurice, S Lyalina, KB Louie, ...
Nature microbiology 4 (12), 2052-2063, 2019
Caloric restriction disrupts the microbiota and colonization resistance
RJ von Schwartzenberg, JE Bisanz, S Lyalina, P Spanogiannopoulos, ...
Nature 595 (7866), 272-277, 2021
Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome
KN Lam, P Spanogiannopoulos, P Soto-Perez, M Alexander, MJ Nalley, ...
Cell reports 37 (5), 2021
A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria
P Spanogiannopoulos, N Waglechner, K Koteva, GD Wright
Proceedings of the National Academy of Sciences 111 (19), 7102-7107, 2014
Genetic basis for the cooperative bioactivation of plant lignans by Eggerthella lenta and other human gut bacteria
EN Bess, JE Bisanz, F Yarza, A Bustion, BE Rich, X Li, S Kitamura, ...
Nature microbiology 5 (1), 56-66, 2020
Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes
P Spanogiannopoulos, M Thaker, K Koteva, N Waglechner, GD Wright
Antimicrobial agents and chemotherapy 56 (10), 5061-5069, 2012
Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance
PJ Stogios, P Spanogiannopoulos, E Evdokimova, O Egorova, T Shakya, ...
Biochemical Journal 454 (2), 191-200, 2013
Rifampin phosphotransferase is an unusual antibiotic resistance kinase
PJ Stogios, G Cox, P Spanogiannopoulos, MC Pillon, N Waglechner, ...
Nature communications 7 (1), 11343, 2016
How to determine the role of the microbiome in drug disposition
JE Bisanz, P Spanogiannopoulos, LM Pieper, AE Bustion, PJ Turnbaugh
Drug Metabolism and Disposition 46 (11), 1588-1595, 2018
Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives
L Zou, P Spanogiannopoulos, LM Pieper, HC Chien, W Cai, N Khuri, ...
Proceedings of the National Academy of Sciences 117 (27), 16009-16018, 2020
Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism
P Spanogiannopoulos, TS Kyaw, BGH Guthrie, PH Bradley, JV Lee, ...
Nature microbiology 7 (10), 1605-1620, 2022
Broad collateral damage of drugs against the gut microbiome
P Spanogiannopoulos, PJ Turnbaugh
Nature Reviews Gastroenterology & Hepatology 15 (8), 457-458, 2018
The enzymes of the rifamycin antibiotic resistome
MD Surette, P Spanogiannopoulos, GD Wright
Accounts of Chemical Research 54 (9), 2065-2075, 2021
The genetic basis for the cooperative bioactivation of plant lignans by a human gut bacterial consortium
EN Bess, JE Bisanz, P Spanogiannopoulos, QY Ang, A Bustion, ...
bioRxiv, 357640, 2018
Drug resistant gut bacteria mimic a host mechanism for anticancer drug clearance
P Spanogiannopoulos, PH Bradley, J Melamed, YNA Malig, KN Lam, ...
bioRxiv 10, 820084, 2019
Exploring Rifamycin Inactivation from the Soil Microbiome
P Spanogiannopoulos
The system can't perform the operation now. Try again later.
Articles 1–20